Literature DB >> 1656076

An Epstein-Barr virus nuclear protein 2 domain essential for transformation is a direct transcriptional activator.

J I Cohen1, E Kieff.   

Abstract

Epstein-Barr virus nuclear protein 2 (EBNA-2) increases mRNA levels of specific viral and cellular genes through direct or indirect effects on upstream regulatory elements. The EBNA-2 domains essential for these effects have been partially defined and correlate with domains important for B-cell growth transformation. To determine whether EBNA-2 has a direct transcriptional activating domain, gene fusions between the DNA-binding domain of GAL4 and EBNA-2 were tested in CHO and B-lymphoma cells for the ability to activate transcription from target plasmids containing GAL4 recognition sites upstream of an adenovirus or murine mammary tumor virus promoter. In B-lymphoma cells, a 37-amino-acid EBNA-2 domain previously identified to be essential for transformation was nearly as strong a transcriptional activator as the activating domain of herpes simplex virus trans-inducing factor VP16. A quadradecapeptide had about 25% of the activating activity of the longer peptide. This first evidence that EBNA-2 directly activates transcription should facilitate the identification of nuclear factors with which EBNA-2 interacts in transactivation and transformation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1656076      PMCID: PMC250250     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  Epstein-Barr virus nuclear protein 2 transactivates a cis-acting CD23 DNA element.

Authors:  F Wang; H Kikutani; S F Tsang; T Kishimoto; E Kieff
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

2.  Epstein-Barr virus nuclear antigen 2 activates transcription of the terminal protein gene.

Authors:  U Zimber-Strobl; K O Suentzenich; G Laux; D Eick; M Cordier; A Calender; M Billaud; G M Lenoir; G W Bornkamm
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

3.  Epstein-Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation.

Authors:  J I Cohen; F Wang; E Kieff
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

4.  Epstein-Barr virus-encoded nuclear antigen 2 activates the viral latent membrane protein promoter by modulating the activity of a negative regulatory element.

Authors:  R Fåhraeus; A Jansson; A Ricksten; A Sjöblom; L Rymo
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

5.  The level of c-fgr RNA is increased by EBNA-2, an Epstein-Barr virus gene required for B-cell immortalization.

Authors:  J C Knutson
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

6.  Epstein-Barr virus nuclear antigen 2 induces expression of the virus-encoded latent membrane protein.

Authors:  S D Abbot; M Rowe; K Cadwallader; A Ricksten; J Gordon; F Wang; L Rymo; A B Rickinson
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

7.  Further developments of protein secondary structure prediction using information theory. New parameters and consideration of residue pairs.

Authors:  J F Gibrat; J Garnier; B Robson
Journal:  J Mol Biol       Date:  1987-12-05       Impact factor: 5.469

8.  Transcription in yeast activated by a putative amphipathic alpha helix linked to a DNA binding unit.

Authors:  E Giniger; M Ptashne
Journal:  Nature       Date:  1987 Dec 17-23       Impact factor: 49.962

9.  Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes.

Authors:  J Sample; L Young; B Martin; T Chatman; E Kieff; A Rickinson; E Kieff
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

10.  Subnuclear localization and phosphorylation of Epstein-Barr virus latent infection nuclear proteins.

Authors:  L Petti; C Sample; E Kieff
Journal:  Virology       Date:  1990-06       Impact factor: 3.616

View more
  71 in total

1.  A role for SKIP in EBNA2 activation of CBF1-repressed promoters.

Authors:  S Zhou; M Fujimuro; J J Hsieh; L Chen; S D Hayward
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

Review 2.  The genetic approach to the Epstein-Barr virus: from basic virology to gene therapy.

Authors:  H J Delecluse; W Hammerschmidt
Journal:  Mol Pathol       Date:  2000-10

3.  Epstein-Barr virus nuclear protein 2 has at least two N-terminal domains that mediate self-association.

Authors:  S Harada; R Yalamanchili; E Kieff
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

4.  EBV nuclear antigen EBNALP dismisses transcription repressors NCoR and RBPJ from enhancers and EBNA2 increases NCoR-deficient RBPJ DNA binding.

Authors:  Daniel Portal; Bo Zhao; Michael A Calderwood; Thomas Sommermann; Eric Johannsen; Elliott Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-25       Impact factor: 11.205

5.  A selectable marker allows investigation of a nontransforming Epstein-Barr virus mutant.

Authors:  A Marchini; J I Cohen; F Wang; E Kieff
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

6.  EBNA2 amino acids 3 to 30 are required for induction of LMP-1 and immortalization maintenance.

Authors:  Alexey V Gordadze; Chisaroka W Onunwor; RongSheng Peng; David Poston; Elisabeth Kremmer; Paul D Ling
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

7.  Four EBNA2 domains are important for EBNALP coactivation.

Authors:  Chih-Wen Peng; Bo Zhao; Elliott Kieff
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

8.  Sequence and functional analysis of EBNA-LP and EBNA2 proteins from nonhuman primate lymphocryptoviruses.

Authors:  R Peng; A V Gordadze; E M Fuentes Pananá; F Wang; J Zong; G S Hayward; J Tan; P D Ling
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

9.  Epstein-Barr virus intrastrain recombination in oral hairy leukoplakia.

Authors:  D M Walling; N Raab-Traub
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

10.  The Epstein-Barr virus EBNA-2 gene in oral hairy leukoplakia: strain variation, genetic recombination, and transcriptional expression.

Authors:  D M Walling; A G Perkins; J Webster-Cyriaque; L Resnick; N Raab-Traub
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.